Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study
2005764 citationsJean‐Yves Reginster, Ego Seeman et al.profile →
The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis
2003522 citationsEric Orwoll, S. Paul et al.Journal of Bone and Mineral Researchprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of S. Adámi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Adámi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Adámi more than expected).
This network shows the impact of papers produced by S. Adámi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Adámi. The network helps show where S. Adámi may publish in the future.
Co-authorship network of co-authors of S. Adámi
This figure shows the co-authorship network connecting the top 25 collaborators of S. Adámi.
A scholar is included among the top collaborators of S. Adámi based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with S. Adámi. S. Adámi is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Ferrari, Serge, S. Adámi, Jacques P. Brown, et al.. (2016). relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of Denosumab (DMAB) treatment. Open Repository and Bibliography (University of Liège).1 indexed citations
2.
Ferrari, Serge, Cesar Libanati, S. Adámi, et al.. (2015). Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment. Open Repository and Bibliography (University of Liège).5 indexed citations
3.
Ferrari, Serge, Cesar Libanati, S. Adámi, et al.. (2014). Percentage of women achieving non-osteoporotic BMD T-scores at the spine and hip over 8 years of denosumab treatment. Open Repository and Bibliography (University of Liège).1 indexed citations
4.
Collette, J., Jean‐Pierre Devogelaer, J.-Y. Reginster, et al.. (2007). Dissociation between bone formation and bone resorption evidenced by changes in biochemical markers of bone turnover in patients treated with strontium ranelate. Calcified Tissue International. 18.1 indexed citations
Seeman, Ego, B. Vellas, C. Roux, et al.. (2004). First demonstration of the efficacy of an anti-osteoporotic treatment in very elderly osteoporotic women.. Journal of Bone and Mineral Research. 19.3 indexed citations
9.
Cline, Gary A., S. Adámi, C. Buckland-Wright, et al.. (2004). Predictors of structural progression in knee osteoarthritis over 24 months. Osteoarthritis and Cartilage. 12.4 indexed citations
10.
Adámi, S., K Hoszowski, Patrice Fardellone, et al.. (2004). Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in Caucasian women with post-menopausal osteoporosis.. Calcified Tissue International. 74.1 indexed citations
11.
Hosking, D., S. Adámi, Dieter Felsenberg, et al.. (2003). Once weekly alendronate produces a greater increase in bone mineral density than daily risedronate. Open Repository and Bibliography (University of Liège).1 indexed citations
12.
Orwoll, Eric, et al.. (2003). The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis. Journal of Bone and Mineral Research. 18(1). 9–17.522 indexed citations breakdown →
13.
Hosking, D., S. Adámi, Dieter Felsenberg, et al.. (2002). Once weekly alendronate produces a greater decrease in bone resorption than does daily risedronate. Open Repository and Bibliography (University of Liège).1 indexed citations
14.
Geusens, P., H Zippel, Bensen Wg, et al.. (2001). Effect of risedronate on the risk of hip fracture in elderly women.. Ghent University Academic Bibliography (Ghent University).11 indexed citations
15.
Hosking, D. J., Hindrik Mulder, S. Adámi, et al.. (2001). Sustained fracture benefit with five years of risedronate in postmenopausal women. Open Repository and Bibliography (University of Liège).1 indexed citations
McClung, Michael R., Richard Eastell, W. Bensen, et al.. (2000). Risedronate reduces hip fracture risk in elderly women with osteoporosis. Open Repository and Bibliography (University of Liège).5 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.